Meeting NewsVideo

VIDEO: Aerie updates Rhopressa, Rocklatan programs

SAN FRANCISCO — At Glaucoma 360: New Horizons Forum, Thomas A. Mitro, president and chief operating officer of Aerie Pharmaceuticals, updates the company’s progress with Rhopressa (netarsudil ophthalmic solution 0.02%) and Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution), and discusses receiving the Glaucoma Research Foundation’s Catalyst Award.

SAN FRANCISCO — At Glaucoma 360: New Horizons Forum, Thomas A. Mitro, president and chief operating officer of Aerie Pharmaceuticals, updates the company’s progress with Rhopressa (netarsudil ophthalmic solution 0.02%) and Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution), and discusses receiving the Glaucoma Research Foundation’s Catalyst Award.

    See more from Glaucoma 360